drugset / Trial / NCT00827008

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

NCT00827008 ↗

Phase 3 Terminated 821 enrolled Merz Pharmaceuticals GmbH
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the long-term safety and tolerability and efficacy of neramexane mesylate in the long-term treatment of subjective tinnitus after a completed double-blind randomized placebo controlled study

Timeline

Start
2009-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Neramexane Small molecule 75 mg Oral

Indications